Buyukkayhan Derya, Ozturk Mehmet Adnan, Kurtoglu Selim, Koklu Esad, Yikilmaz Ali
Department of Neonatology, Cumhuriyet University School of Medicine, Sivas, Turkey.
J Pediatr Endocrinol Metab. 2009 Nov;22(11):1027-31. doi: 10.1515/jpem.2009.22.11.1027.
To assess the effect of antenatal betamethasone use on adrenal gland size and adrenal hormones in preterm neonates who had gestational ages of 27-36 weeks.
Sixty-six neonates divided into two groups: betamethasone group, whose mothers received betamethasone 12 mg two times 24 h apart, and no betamethasone group, whose mothers did not receive any steroid agent during the antenatal period. Serum 17-hydroxyprogesterone (17-OHP) levels and cortisol levels were measured during the first six hours of life. In addition, adrenal gland length and width were determined on the first day of life. Hormone tests and ultrasonographic evaluation were repeated on the fifth day of life.
We found statistically significant reductions in 17-OHP and cortisol levels at birth in corticosteroid-exposed neonates (p < 0.05). There was no significant difference between the study groups with regard to adrenal gland length and width (p > 0.05).
This study demonstrates that betamethasone use in preterm neonates reduces endogenous 17-OHP and cortisol levels; however, it has no effect on adrenal gland size.
评估产前使用倍他米松对孕周为27 - 36周的早产儿肾上腺大小及肾上腺激素的影响。
66例新生儿分为两组：倍他米松组，其母亲在产前24小时内接受两次12毫克倍他米松治疗；非倍他米松组，其母亲在产前未接受任何类固醇药物治疗。在出生后前6小时测量血清17 - 羟孕酮（17 - OHP）水平和皮质醇水平。此外，在出生第一天测定肾上腺的长度和宽度。在出生后第5天重复进行激素检测和超声评估。
我们发现，暴露于皮质类固醇的新生儿出生时17 - OHP和皮质醇水平有统计学意义的降低（p < 0.05）。研究组之间在肾上腺长度和宽度方面无显著差异（p > 0.05）。
本研究表明，在早产儿中使用倍他米松可降低内源性17 - OHP和皮质醇水平；然而，对肾上腺大小无影响。
